Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OrthoCellix
Malvern, Pennsylvania, United Statesorthocellix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeoCart® is a first-in-class autologous cell therapy designed to restore knee cartilage; it has received FDA RMAT designation, prior clinical validation, and is expected to initiate a pivotal phase 3 trial in late 2025. A previous trial failed to demonstrate statistical superiority to chondroplasty, posing a key risk.
- Therapeutic areas
- Rheumatology
- Modalities
- Cell therapyAutologous cartilage implant
- Industry
- Biotech
02
Partnerships
No formally disclosed ongoing pharma/biotech partnerships; Ocugen supports manufacturing and infrastructureCarisma’s prior partnerships (e.g., Moderna) are discontinued as part of merger
Beyond the preview
Go deeper on OrthoCellix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OrthoCellix.